Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAVA-1207 in therapy refractory mCRPC
NCT05369000Phase 1Terminated
- Sponsor
- LAVA Therapeutics
- Start
- Jan 2022
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of LAVA-1207 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by LAVA Therapeutics. Primary endpoints: Frequency and severity of Adverse Events at 24 months and Frequency and type of Dose Limiting Toxicities at 28 days. Started Jan 2022; status: terminated.
02
Drugs
LAVA-1207
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05369000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369000.